ZELSUVMI
Growthberdazimer
NDATOPICALGEL
Approved
Jan 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELSUVMI (berdazimer) is a topical gel approved in January 2024 for dermatological use. The specific mechanism of action and indication are not yet publicly detailed in standard databases, suggesting a recently launched or niche indication. As a topical formulation, it targets localized skin conditions with direct application.
Growth9.2 years to LOE
Early-stage growth product with no current competitive pressure, offering opportunity to build brand awareness and establish market position in a new or underserved indication.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZELSUVMI offers a career opportunity in a newly launched, uncontested dermatology product with nine years of patent protection and strong growth potential. Joining the team now positions you to build brand equity from launch and establish category-defining practices in a focused specialty market.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.